RxDoctor Payments Data

Calvin Wong, MD

Sports Medicine · San Diego, CANPI 1962400531

Payments from drug & device makers

$6,313in general payments, 2019–2025

Across 190 payments — averaging $33.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Gilead$1K
  • AstraZeneca$794
  • Lilly USA, LLC$710
  • Viiv Healthcare Company$678
  • Johnson & Johnson$414
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$6,28099%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,313 in reported general payments places this provider in the 65th percentile of 662 sports medicine providers in California.

See all sports medicine providers in California

Medicare billing

Part B allowed, 2024
$34,725
Medicare patients
123
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$44,183
FarxigaDapagliflozin Propanediol34$34,937
JardianceEmpagliflozin15$19,354
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$14,216
Atorvastatin Calcium127$1,419
Quetiapine Fumarate21$1,147
Gabapentin42$967
Albuterol Sulfate HfaAlbuterol Sulfate31$763
Fluticasone Propionate25$735
Diclofenac Sodium15$699
Losartan Potassium45$520
Metoprolol Succinate21$512
Tamsulosin Hcl24$352
Potassium Chloride20$335
Rosuvastatin Calcium18$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$794$49,15351 claims
Novo NordiskOzempic$1,419$44,18333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 662 sports medicine providers in California.

Other sports medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →